A carregar...
Olaparib and Pembrolizumab Treatment for BRCA1-Mutated and PD-L1-Positive Intrahepatic Cholangiocarcinoma Recurrence and Metastasis: A Case Report
Olaparib has been applied as monotherapy to treat ovarian and breast cancer patients with malignant or suspected malignant BRCA1/2 mutations. Pembrolizumab has been approved to treat unresectable or metastatic tumors in patients who exhibited progression after previous treatment, regardless of histo...
Na minha lista:
| Publicado no: | Onco Targets Ther |
|---|---|
| Main Authors: | , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Dove
2020
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7342556/ https://ncbi.nlm.nih.gov/pubmed/32753881 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OTT.S250454 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|